ADMA Biologics jumps on revenue beat, upbeat FY outlook
12/05/2022 17:06
** Shares of plasma-therapy maker ADMA.O rise 22.4% to
$1.75 - stock among top pct gainers on the Nasdaq Biotechnology
Index .NBI
** ADMA posts total Q1 revenue of about $29.1 mln, above
analysts' estimates of $28.2 mln urn:newsml:reuters.com:*:nGNX8M8rVq
** Reports revenue above estimates for sixth straight
quarter - Refinitiv
** Sees FY 2022 total revenue of $130 mln or more vs est of
$128.5 mln
** Including Thursday's session, ADMA up nearly 12% vs about
27% decline in NBI this year
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))